Humanwell Healthcare (600079.SH): HW211026 ointment enters Phase II clinical trial research.
ST Fu (600079.SH) announced that its fully-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd. (referred to as "Research Institute Ltd."), recently disclosed the registration information for the phase II clinical trial of HW211026 ointment on the National Medical Products Administration's Drug Clinical Trial Registration and Information Disclosure Platform.
The trial is titled: A multicenter, open-label, dose exploration phase II clinical study to evaluate the effectiveness and safety of HW211026 ointment in the treatment of actinic keratosis.
The purpose of the trial is to assess the effectiveness of HW211026 ointment in treating actinic keratosis.
Humanwell Healthcare (600079.SH) announced that its wholly-owned subsidiary, Hubei Biomedical Industry Technology Research Institute Co., Ltd. (referred to as "Research Institute Co., Ltd."), recently disclosed the registration information of the phase II clinical trial of HW211026 ointment on the National Medical Products Administration Drug Clinical Trial Registration and Information Disclosure Platform. The trial is titled: A multicenter, open-label, exploratory phase II clinical study to evaluate the effectiveness and safety of HW211026 ointment in the treatment of actinic keratosis. The objective is to assess the effectiveness of HW211026 ointment in treating actinic keratosis.
Related Articles
CHAOJU EYE CARE (02219) spent HKD 403,400 to repurchase 158,000 shares on July 9th.
WEIYE HOLDINGS (01570): The Board of Directors will convene a special shareholders' meeting as soon as possible for shareholders' consideration and approval of changing the company's English name as appropriate.
UBS: Jiangsu Hengrui Pharmaceuticals (01276) weight-loss drug HRS-7535 clinical data positive, valuation attractive, reiterate "buy" rating.
CHAOJU EYE CARE (02219) spent HKD 403,400 to repurchase 158,000 shares on July 9th.
WEIYE HOLDINGS (01570): The Board of Directors will convene a special shareholders' meeting as soon as possible for shareholders' consideration and approval of changing the company's English name as appropriate.
UBS: Jiangsu Hengrui Pharmaceuticals (01276) weight-loss drug HRS-7535 clinical data positive, valuation attractive, reiterate "buy" rating.
RECOMMEND
